Heparin and cAMP modulators interact during pre-in vitro maturation to affect mouse and human oocyte meiosis and developmental competence

Hai-tao Zeng1,2, Zi Ren1,3, Luis Guzman4,5, Xiaqian Wang1, Melanie L. Sutton-McDowall1, Lesley J. Ritter1, Michel De Vos5, Johan Smitz4, Jeremy G. Thompson1, and Robert B. Gilchrist1,*

1Research Centre for Reproductive Health, Robinson Institute, and Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health, Medical School, University of Adelaide, Adelaide, Australia 2Department of Obstetrics and Gynecology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China 3Center for Reproductive Medicine, General Hospital of Guangdong, Guangzhou, People’s Republic of China 4Laboratory of Follicular Biology, UZ Brussel, Brussels, Belgium 5Center for Reproductive Medicine, UZ Brussel, Brussels, Belgium

*Correspondence address. Fax: +61-8-83038177; E-mail: robert.gilchrist@adelaide.edu.au

Submitted on November 16, 2012; resubmitted on February 5, 2013; accepted on February 28, 2013

STUDY QUESTION: Does heparin ablate the advantageous effects of cyclic adenosine mono-phosphate (cAMP) modulators during pre-in vitro maturation (IVM) and have a deleterious effect in standard oocyte IVM?

SUMMARY ANSWER: Heparin interrupts energy metabolism and meiotic progression and adversely affects subsequent development of oocytes under conditions of elevated cAMP levels in cumulus-oocyte complexes (COCs) after pre-IVM treatment with forskolin.

WHAT IS KNOWN ALREADY: In animal IVM studies, artificial regulation of meiotic resumption by cAMP-elevating agents improves subsequent oocyte developmental competence. Heparin has no effect on spontaneous, FSH- or epidermal growth factor (EGF)-stimulated meiotic maturation.

STUDY DESIGN, SIZE, DURATION: An in vitro cross-sectional study was conducted using immature mouse and human COCs. Depending on individual experimental design, COCs were treated during pre-IVM with or without heparin, in the presence or absence of forskolin and/or 3-isobutyl-1-methylxanthine (IBMX), and then COC function was assessed by various means.

PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Forty-two women with polycystic ovaries (PCOs) or polycystic ovarian syndrome (PCOS) donated COCs after oocyte retrieval in a non-hCG-triggered IVM cycle. COCs were collected in pre-IVM treatments and then cultured for 40 h and meiotic progression was assessed. COCs from 21- to 24-day-old female CBA F1 mice were collected 46 h after stimulation with equine chorionic gonadotrophin. Following treatments, COCs were checked for meiotic progression. Effects on mouse oocyte metabolism were measured by assessing oocyte mitochondrial membrane potential using JC-1 staining and oocyte ATP content. Post-IVM mouse oocyte developmental competence was assessed by in vitro fertilization and embryo production. Blastocyst quality was evaluated by differential staining of inner cell mass (ICM) and trophectoderm (TE) layers.

MAIN RESULTS AND THE ROLE OF CHANCE: In the absence of heparin in pre-IVM culture, the addition of cAMP modulators did not affect human oocyte MII competence after 40 h. In standard IVM, heparin supplementation in pre-IVM did not affect MII competence; however, when heparin was combined with cAMP modulators, MII competence was significantly reduced from 65 to 15% (P < 0.05). In mouse experiments, heparin alone in pre-IVM significantly delayed germinal vesicle breakdown (GVBD) so that fewer GVBDs were observed at 0 and 1 h of IVM (P < 0.05), but not by 2 or 3 h of IVM. Combined treatment with IBMX and forskolin in the pre-IVM medium produced a large delay in GVBD such that no COCs exhibited GVBD in the first 1 h of IVM, and the addition of heparin in pre-IVM further significantly delayed the progression of GVBD (P < 0.05), in a dose-dependent manner (P < 0.01). Combined IBMX and forskolin treatment of mouse...
Recovery of immature oocytes followed by in vitro maturation (IVM) is a potentially useful treatment to generate mature oocytes for a range of clinical applications, including human infertility treatment and fertility preservation. The major advantages of IVM are avoidance of the risk of ovarian hyperstimulation syndrome, reduced cost, simplified treatment and reduced anxiety that the short-term and long-term side effects of repeated ovarian stimulation may have on maternal and fetal health (Chian et al., 2004). However, in comparison with conventional in vitro fertilization (IVF), in vitro matured oocytes have been shown to be compromised in embryo quality and developmental potential (Trounson et al., 2001). In general, current approaches to IVM have much lower pregnancy rates than conventional IVF, with implantation rates rarely exceeding 10–15% per embryo transferred and reduced rates of live births (Nogueira et al., 2004). However, in vitro matured oocytes have been shown to be compromised in embryo quality and developmental potential (Trounson et al., 2001). In general, current approaches to IVM have much lower pregnancy rates than conventional IVF, with implantation rates rarely exceeding 10–15% per embryo transferred and higher early pregnancy losses (Smitz et al., 2011).

An innovative approach to IVM for application in infertility treatment and fertility preservation is required to bring this patient-friendly treatment into routine practice. A recent significant clinical innovation is the approach of vitrifying all embryos in an IVM pick-up cycle, which substantially increases implantation rates (De Vos et al., 2011; Guzman et al., 2012). In terms of laboratory approaches, solid gains in the improvement of oocyte competence have been achieved in animal studies by managing cyclic adenosine mono-phosphate (cAMP) levels during IVM (reviewed; Gilchrist, 2011). cAMP plays a critical role in maintaining mammalian oocyte meiotic arrest and inducing maturation in mammalian oocytes (Conti et al., 2012). Relatively high levels of cAMP within the oocyte are essential to maintain meiotic arrest, whereas a drop in intra-oocyte concentration of cAMP enables resumption of meiosis and maturation (Sela-Abramovich et al., 2006), and this is the mechanism that allows oocytes to spontaneously mature during IVM. The cornerstone of modern approaches to IVM is to control cumulus–oocyte complex (COC) cAMP levels to allow synchronization of nuclear and cytoplasmic maturation processes within the oocyte (Gilchrist, 2011; Smitz et al., 2011). A key outcome of this approach is the maintenance in vitro of cumulus–oocyte gap junctions, with the objective to prolong the oocyte maturation period to promote sustained interaction between the immature oocytes with adequately conditioned cumulus cells (Gilchrist, 2011; Luciano et al., 2011). Maintenance of an appropriate cAMP concentration seems to be an important requirement to promote chromatin transition and gradual transcriptional silencing, as part of final oocyte differentiation (Luciano et al., 2011). A large body of animal and human literature demonstrates that artificial regulation of meiotic resumption by cAMP elevating agents improves subsequent oocyte developmental competence (Funahashi et al., 1997; Luciano et al., 1999, 2004, 2011; Nogueira et al., 2003a,b, 2006; Thomas et al., 2004). Our previous study found that combined treatment of COCs with the cAMP modulators cilostamide (type 3-specific phosphodiesterase (PDE) inhibitor) and forskolin, positively influenced human oocyte developmental competence, by exhibiting a synergistic effect on the prevention of loss of gap junctions and the resumption of meiosis, by increasing COC cAMP levels (Shu et al., 2008). In another approach termed simulated physiological oocyte maturation (SPOM), we showed, using mouse and cow COCs, that the first 1–2 h after oocyte collection is critically important and that treatment with forskolin and 3-isobutyl-1-methylxanthine (IBMX, a non-specific PDE inhibitor) during this period has profound long-term consequences on oocyte developmental programming (Albuz et al., 2010).

Clinical IVM pick-up aspirates are usually blood laden, which may block the thin IVM aspiration needle, and typically makes the tightly compacted COCs difficult to identify in the aspirate. Heparin acts as an anticoagulant, preventing the formation of clots and extension of existing clots. It is widely used as an injectable anticoagulant in clinical practice, and can also be used to form an inner anticoagulant surface on various experimental and medical devices. Therefore, during the clinical practice of IVM and IVF, follicular fluid is collected in tubes containing saline or PBS containing heparin. Heparin is sometimes added...
to collection media in animal IVM research laboratories, although, in some species, it is often omitted. When the SPOM approach (Albuz et al., 2010) was applied in a clinical experiment, we noted an unexpected adverse interaction between heparin and cAMP regulators that prevented human oocyte maturation. Therefore, in this study, we hypothesized that heparin ablates the advantageous effects of cAMP modulators during pre-IVM, but has no deleterious effects in standard laboratory IVM practice. Due to the natural shortage of good quality human oocytes for research purposes, the bulk of the mechanistic investigations of this hypothesis were conducted using the mouse model, where the same phenomenon was evident.

**Materials and Methods**

**Experimental approvals and reagents**

All human oocyte experiments were conducted in Belgium at UZ Brussel, whereas all mouse experiments were conducted at the University of Adelaide, Australia. Human experiments were approved by the local ethics committee and each of the oocyte donors gave written informed consent. All mouse experimental protocols and animal handling procedures were reviewed and approved by the University of Adelaide Animal Ethics Committee. All of the reagents were purchased from Sigma (St. Louis, MO, USA) unless otherwise stated. Three kinds of heparin purified from porcine intestinal mucosa were used in this study: one high molecular weight (17–19 kDa) heparin (Sigma, H3393-1MU) and two low molecular weight (~6 kDa) liquid heparins from DBL (Hospira Australia Pty Ltd, New Zealand) and Leo (LEO Pharma, Belgium). All mouse experiments were conducted with DBL heparin (DBL) unless otherwise stated.

**Clinical and laboratory aspects of human IVM**

Forty-two consecutive patients and healthy oocyte donors with ultrasound-only PCOs or PCOS consented to donate oocytes for IVM research at UZ Brussel. Briefly, all women received 150 IU/day highly purified human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals) for 3 days, starting on Day 3 after spontaneous menstruation or withdrawal bleeding. An ovarian ultrasound scan was performed on Day 6 to rule out the emergence of a dominant follicle. All patients underwent transvaginal ovarian puncture for immature oocyte retrieval on cycle Day 7. No hCG trigger was administered. COCs were retrieved with a 17-gauge single-lumen needle (K-OPS-1230-VUB; Cook Medical, Brisbane, Australia), with an aspiration pressure of 70 mmHg and collected into pre-IVM media from Cook Medical; either version 1 (without cAMP modulators) or version 2 (with forskolin and IBMX), with or without heparin at 10 IU/ml (Heparin Leo®, Leo Pharma, Belgium). Follicular aspirates were filtered ( Falcon 1060; 70 mm mesh size) and COCs were collected from the culture dish and incubated in pre-IVM media with treatments for 1 h. Collected COCs were then washed and cultured individually in 96-well dishes (Costar 3696; Corning, New York, USA), each well containing 75 μl of IVM culture media (version 1; Cook Medical) that had been pre-equilibrated at 37 °C and 6% CO2 and supplemented with 100 mIU/ml FSH and 0.25 μM cAMP modulator. After 40 h of IVM culture, COCs were mechanical dissociated using hyaluronidase (Cook Medical) under a stereomicroscope and maturation was assessed under an inverted microscope. These pre-IVM and IVM treatments were designed to test the efficacy of the SPOM IVM approach in humans under clinical conditions (Albuz et al., 2010).

**Mouse COC collection and pre-IVM treatments**

Immature female CBA F1 mice that were 21–24 days of age were housed in a temperature- and light-controlled room. Immature COCs were collected 46 h after the administration of 5 IU of equine chorionic gonadotrophin (eCG; Folligon, Intervet, The Netherlands). Puncture of mouse ovaries and collection of COCs from large antral follicles was performed in HEPES-buffered alpha minimal essential medium (αMEM: Invitrogen, Carlsbad, CA, USA) supplemented with 3 mg/ml bovine serum albumin (BSA; ICP Biological™, New Zealand) and 1 mg/ml fetuin. All experimental interventions in this study were conducted during the 1 h pre-IVM phase and hence were conducted in collection medium in HEPES-αMEM medium. Depending on individual experimental design, COCs were exposed during pre-IVM to the adenylyl cyclase activator, forskolin (50 μM), with or without the PDE inhibitor IBMX (50 μM) and heparin (50 IU/ml). Millimolar stock concentrations of the forskolin and IBMX were stored at −20 °C dissolved in anhydrous dimethylsulphoxide and were diluted fresh for each experiment. COCs were maintained in pre-IVM treatments under atmospheric conditions at 37 °C for 1 h. At the end of the pre-IVM phase, COCs were washed twice in their respective IVM treatments, before transfer to IVM drops.

**Mouse IVM**

Mouse COCs were matured in bicarbonate-buffered αMEM medium supplemented with 3 mg/ml BSA. For experiments measuring germinal vesicle breakdown (GVBD) as the primary outcome, COCs were cultured in HEPES-buffered αMEM medium supplemented with BSA without FSH for 1 h at 37 °C under atmospheric conditions, or for 3 h at 37 °C in pre-equilibrated bicarbonate-buffered αMEM medium (with BSA, without FSH) in 6% CO2 in humidified air. In the experiments where meiosis was assessed, COCs were denuded of cumulus cells at the designated time points and checked for meiotic progression by light microscopy. Where IVM preceded IVF, groups of 30–40 COCs were matured in 500 μl drops of pre-equilibrated bicarbonate-buffered αMEM medium supplemented with 50 mIU/ml recombinant human FSH (Purogen, Organon), BSA and 1 mg/ml fetuin, overlaid with mineral oil and incubated at 37 °C with 5% CO2 in humidified air for 18 h prior to IVF.

**Mouse IVF and embryo culture**

The effect of treatments on oocyte developmental competence was assessed by examining the capacity of the oocyte post-IVM to support pre-implantation embryo development. Mouse IVF and embryo culture were performed as previously described (Albuz et al., 2010). All media used were the Vitro Research Media series generously donated by Cook Medical (Brisbane, Australia). Mouse IVM/embryo experiments were replicated four times.

**Differential staining of mouse blastocysts**

On Day 5 of embryo culture, blastocysts and hatching blastocysts were subjected to a differential staining protocol for the identification of cells within the ICM and TE layers (Dunning et al., 2010). The zona was dissolved by incubation in 0.5% pronase at 37 °C. Blastocysts were then transferred to 10 mM tri-nitrobenzene sulfonic acid for 10 min at 4 °C, followed by incubation in 0.1 mg/ml of anti-dinitrophenyl-BSA for 10 min at 37 °C, then 5 min at 37 °C in guinea pig serum containing 10 μg/ml of propidium iodide. Blastocysts were then stained overnight in 6 μg/ml of bisbenzimide in ethanol at 4 °C. The following day, blastocysts were washed in 100% ethanol and mounted on a siliconised slide in a glycerol drop. The number of pink (TE) and blue (ICM) fluorescent cells was assessed, blinded to treatment group, using a fluorescent microscope and Hg
Assessment of mouse oocyte metabolism after pre-IVM culture

To determine ATP levels within oocytes, COCs were cultured in their respective pre-IVM treatments for 1 h and then denuded of cumulus cells. For each sample preparation, 10 oocytes from each treatment were collected in 10 μl of ice cold distilled water and snap frozen and stored at −80°C for later analysis. The measurement of ATP content in oocytes was performed with an ApoSENSOR™ ATP Assay Kit (BioVision, CA, USA) according to the manufacturer’s instructions. The assay utilizes the enzyme luciferase to catalyse the formation of light from ATP and luciferin, and light was measured by using a TRIAD™ Series Verification Plate (DYNEX, VA, USA). A duplicated five-point standard curve (0, 0.5, 1, 2 and 3 μM of ATP) was included in the assay. The oocyte ATP content was calculated using the formula derived from the linear regression of the standard curve. Five replicate experiments were conducted using 80–120 oocytes/treatment/replicate.

The mitochondrial membrane potential-sensitive fluorescence dye, JC-1 (Molecular Probes, Eugene, OR, USA), was used to measure the activity of oocyte mitochondria. Low-polarized mitochondria (ΔΨm ≤ −100 mV) fluoresce green and high-polarized mitochondria (ΔΨm ≥ −140 mV) fluoresce yellow-red, reflecting the formation of JC-1 multimers or J-aggregates (Reers et al., 1995). The stock concentration of the dye was 1 mM in dimethyl sulfoxide. The dye was diluted in culture medium before use. COCs were cultured in their respective pre-IVM treatments for 1 h, then denuded of cumulus cells and oocytes were cultured for 15 min in their respective treatments with 2 μM JC-1. Oocyte fluorescence was observed using a narrow green filter (490–540 nm) and a narrow red filter (570–620 nm), using a Fluoview FV10i Confocal Microscope (Olympus, Japan). The laser-power and photomultiplier settings were kept constant for all experiments. A single optical scan through the centre of the oocyte was used for the analysis. The images were processed, and red and green fluorescence intensities of JC-1 in oocytes were measured and analysed using the inbuilt software of the Fluoview FV10i Confocal Microscope. Three replicate experiments were conducted using 10–20 oocytes/treatment/replicate.

Statistical analysis

Statistical analyses were conducted using the Statistical Package for Social Sciences 18.0 (SPSS, Chicago, IL, USA). Treatment effects were assessed by χ² test (human COC experiment) or one-way analysis of variance followed by either Dunnett’s or Bonferroni’s multiple-comparison post hoc tests to identify individual differences between means. All values are presented as means with their corresponding SEM. Statistical significance was set at P < 0.05.

Results

Effect of heparin on meiotic maturation of human COCs treated with/without cAMP modulators

In the absence of heparin in pre-IVM, the addition of cAMP modulators (pre-IVM, forskolin + IBMX; IVM, cilostamide) did not affect human oocyte MII competence after 40 h (Fig. 1A). Heparin alone in pre-IVM did not appreciably affect MII competence; however, when combined with cAMP modulators, MII competence was significantly (P < 0.05) reduced from 65 to 15% (Fig. 1B), suggesting an adverse interaction between pre-IVM heparin and the pre-IVM cAMP modulators forskolin and IBMX, on human oocyte maturation. Hence, subsequent experiments were conducted using the mouse experimental model to investigate, in further detail, the nature of such an interaction.

Effect of heparin with/without IBMX and forskolin in pre-IVM on subsequent GVBD of mouse COCs

As expected, treatment with IBMX and/or forskolin during pre-IVM significantly lowered the rates of GVBD at designated time points in IVM, when compared with controls (P < 0.05). As shown in Fig. 2A and B, heparin alone in pre-IVM also significantly (P < 0.05) decreased GVBD at 0 and 1 h of IVM, but not by 2 or 3 h of IVM. Furthermore, an additive effect of heparin and IBMX and/or forskolin in pre-IVM was observed, whereby heparin further inhibited GVBD in each IBMX/forskolin treatment combination (P < 0.05). In the combined treatment of IBMX and forskolin in pre-IVM, oocytes commenced GVBD after 2 h of IVM; however, the addition of heparin in pre-IVM further significantly decreased GVBD rates for the first 3 h of the IVM phase (P < 0.05; Fig. 2B).

As there are many different heparin variants, each with different vehicles and preservatives, we examined the capacity of different types of heparin to interact with cAMP modulators in pre-IVM, on subsequent meiotic resumption in IVM. When used together with IBMX and forskolin in pre-IVM, both low-molecular-weight liquid injectable heparin variants containing preservatives (~6 kDa; Leo and DBL), and a high-molecular-weight, ostensibly preservative-free,
powdered heparin (17–19 kDa; Sigma), inhibited GVBD to comparable extents after 2 h of IVM (P < 0.05, Fig. 3A). In the presence of IBMX and forskolin in pre-IVM, there was a significant dose-dependent inhibition of oocyte GVBD during the IVM phase (P < 0.01, Fig. 3B). This experiment yielded higher GVBD rates than those in Fig. 2, which we attribute to a different operator using subtly different denuding techniques and efficiency of assessment which, in the absence of a PDE inhibitor in IVM, have large effects on GVBD rates in mouse oocytes. All other mouse experiments in this study used DBL heparin at 50 IU/ml.

Effect of IBMX, forskolin and heparin on energy metabolism in mouse oocytes

cAMP is generated from ATP and hence treatment during pre-IVM with IBMX and/or forskolin is likely to impact on COC metabolism. Relative to levels at collection from the follicle, intra-oocyte ATP levels did not change after 1 h of pre-IVM treated with 50 μM IBMX or 50 μM forskolin (Fig. 4A). However, combined IBMX and forskolin treatment of COCs during pre-IVM significantly increased ATP concentration in the oocyte after 1 h (P < 0.05). Heparin had no effect on oocyte ATP levels in the presence of IBMX, tended to decrease levels in the presence of forskolin (P = 0.102), and abolished the increase in ATP concentration in the presence of IBMX and forskolin (P < 0.05), generating less than half of the ATP content (Fig. 4A). This latter adverse combinational effect was negated when COCs were collected in heparin and IBMX for 15 min, washed and then cultured for 45 min in IBMX and forskolin without heparin, to
Heparin and cAMP modulators interact

The extent that ATP levels were restored to levels comparable with IBMX + forskolin ($P > 0.05$; Fig. 4A).

We also examined oocyte mitochondrial activity after pre-IVM treatments using the mitochondrial membrane stain JC-1. As shown in Fig. 4B and C, in the control group of COCs undergoing GVBD, the ratio of red/green fluorescence intensity was more than doubled ($P < 0.05$) from 0 to 1 h of pre-IVM culture. Although the ratio was also significantly increased from collection to 1 h when treating with heparin ($P < 0.01$), it was nonetheless lower than the 1 h control ($P < 0.01$). With any combination of IBMX $\pm$ forskolin $\pm$ heparin, the majority of oocytes were still at the GV stage after 1 h of pre-IVM (Figs 2 and 4C), when JC-1 staining was performed. When treated with IBMX, regardless of the presence of heparin, oocyte mitochondrial membrane hyper-polarization levels were significantly ($P < 0.05$) lower than in control oocytes (1 h). In the absence of heparin, when compared with IBMX, forskolin seemed more effective at increasing the ratio of red/green fluorescence intensity in oocytes ($P < 0.01$). IBMX notably amplified this stimulating effect of forskolin (Fig. 4B and C; $P < 0.05$), supporting the observed elevated ATP levels in this treatment group (Fig. 4A). However, heparin abolished the stimulation of mitochondrial function by forskolin ($P < 0.01$), and it was more apparent in treatment with IBMX and forskolin, with less than half the ratio of red/green fluorescence intensity in these oocytes ($P < 0.01$).

**Figure 4** Effect of heparin in pre-IVM with and without IBMX and forskolin on mouse oocyte ATP content (A) and mitochondrial activity (B and C) at the end of pre-IVM. Mouse COCs were collected; without culture (0 h control), or COCs were held in each treatment medium for 1 h (pre-IVM), including in one treatment where COCs were exposed to IBMX + heparin for 15 min (IH--15 min) followed by IBMX + forskolin without heparin for 45 min (IF--45 min). Thereafter COCs were denuded, washed and either immediately snap frozen for ATP measurement (A), or cultured for a further 15 min with JC-1 before assessment of mitochondrial function (B and C). In (A), a total of 600 oocytes in each treatment were assayed in 50 oocytes/test tube. (B) Columns from left to right represent the following number of oocytes (41, 25, 46, 28, 66, 44, 39, 60 and 55). In (C) red and green fluorescence indicates high and low polarized mitochondria, respectively. Data points represent mean $\pm$ SEM of five (A) and three (B) replicate experiments. Means with no common superscripts are significantly different ($P < 0.05$).

**Effect of heparin with/without IBMX and forskolin in pre-IVM on subsequent maturation and developmental competence of mouse oocytes**

To determine the developmental consequences of pre-IVM treatment with heparin with/without IBMX and forskolin, following pre-IVM, COCs were subjected to standard IVM (with FSH), IVF and embryo culture to Day 5 (Fig. 5). While IBMX and forskolin initially delayed meiotic resumption (Fig. 2), these oocytes were not delayed in reaching MII, but rather the treatment promoted increased maturation of oocytes to the polar body stage compared with the control (Fig. 5A, 87.3%, $P < 0.05$). In the absence of IBMX + forskolin, heparin had no effect on the maturation rate when compared with control ($P > 0.05$), but significantly ($P < 0.05$) reduced maturation in the presence of IBMX + forskolin. Compared with the control, pre-IVM with IBMX and forskolin significantly increased cleavage, blastocyst and hatched blastocyst rates (Fig. 5B–D, $P < 0.05$). IBMX and forskolin also improved embryo quality, reflected in an increased ICM cell number and a higher ratio of ICM/total cells compared with the control (Fig. 5E and F, $P < 0.05$). Heparin alone had no adverse effect on cleavage or embryo development rates or on embryo quality compared with the control ($P < 0.05$). However, when combined with IBMX and forskolin, heparin significantly decreased the cleavage rate (Fig. 5B; $P < 0.05$) compared with the control group, and notably antagonised the beneficial effects of forskolin and IBMX, in terms of cleavage and hatched blastocyst rates, ICM cell numbers and ICM/total cell numbers (Fig. 5; $P < 0.05$).

As heparin + IBMX + forskolin combined in pre-IVM adversely affected the majority of parameters of COC function assessed in this study, but the combination of heparin + IBMX only weakly inhibited GVBD of oocytes and had no harm on mitochondrial activity.
(Figs 2 and 4), the effect of this treatment on oocyte maturation and subsequent developmental competence was assessed. Compared with the control, treatment during pre-IVM with heparin and IBMX for 1 h had no effect on oocyte maturation, cleavage, blastocyst or hatched blastocyst rates, or on subsequent blastocyst cell numbers (Fig. 5). When COCs were collected in medium with IBMX and heparin for 15 min, and then washed and transferred to medium with IBMX and forskolin without heparin for 45 min [IBMX + forskolin (IF–45 min)], after pre-IVM COCs were washed, cultured in treatment-free IVM medium for 18 h, and then either; denuded and assessed for meiotic maturation (A), or COCs were fertilised in vitro and cultured for 5 days (B–D). Blastocyst quality was assessed with differential staining by cell number of ICM (E) and ratio of ICM/total blastocyst cell number (F). Columns of (A–D) from left to right represent the following number of oocytes (109, 127, 130, 137, 119 and 134), and columns of (E) and (F) from left to right represent the following number of analysed blastocysts (23, 19, 29, 19, 22 and 23). Data points represent mean + SEM of four replicates. Means with no common superscripts are significantly different ($P < 0.05$).

**Figure 5** Effect of heparin in pre-IVM with and without IBMX and forskolin on the subsequent meiotic and developmental competence of mouse oocytes. Mouse COCs were collected and held in each treatment medium for 1 h (pre-IVM), including in one treatment where COCs were exposed to IBMX + heparin for 15 min (IH–15 min) followed by IBMX + forskolin without heparin for 45 min (IF–45 min). After pre-IVM COCs were washed, cultured in treatment-free IVM medium for 18 h, and then either; denuded and assessed for meiotic maturation (A), or COCs were fertilised in vitro and cultured for 5 days (B–D). Blastocyst quality was assessed with differential staining by cell number of ICM (E) and ratio of ICM/total blastocyst cell number (F). Columns of (A–D) from left to right represent the following number of oocytes (109, 127, 130, 137, 119 and 134), and columns of (E) and (F) from left to right represent the following number of analysed blastocysts (23, 19, 29, 19, 22 and 23). Data points represent mean + SEM of four replicates. Means with no common superscripts are significantly different ($P < 0.05$).

**Discussion**

Mammalian oocyte maturation in vitro and subsequent developmental competence is influenced to a great extent by the culture media and culture conditions employed, including the addition of hormones, growth factors and other specific signal transduction regulators (Gilchrist, 2011). There is now a large body of evidence that management of oocyte and cumulus cell cAMP during IVM is desirable and is an effective means to enhance oocyte developmental competence (Smits et al., 2011). Consistent with previous studies using a cAMP-mediated biphasic-IVM approach (Funahashi et al., 1997; Nogueira et al., 2003a,b; Shu et al., 2008; Vanhoutte et al., 2009) and with SPOM (Albuz et al., 2010), compared with standard IVM, elevating COC cAMP, in this study, generated higher rates of mouse oocyte maturation and embryo development and improved embryo quality, as reflected in an increased hatched blastocyst rate and ICM size. This was achieved by rapidly increasing cAMP levels in COCs with forskolin and IBMX for just the 1 h pre-IVM phase. However, under such elevated cAMP conditions, the inclusion of heparin in pre-IVM media affected human and mouse oocyte maturation, and had a notable detrimental interaction with forskolin on mouse oocyte metabolism and subsequent developmental potential. In contrast, collection medium with IBMX and heparin caused a transient arrest in oocyte meiotic resumption, without compromising subsequent maturation and
fertilization, suggesting that this may be a good clinical option for oocyte collection when using cAMP modulators.

In our study, in the absence of cAMP modulators, heparin had no effect on the capacity of human or mouse oocytes to complete meiosis, but delayed mouse oocyte meiotic resumption. Heparin did not completely prevent GVBD during spontaneous maturation, but delayed it so that after 2 h oocytes exhibited similar GVBD rates to spontaneously maturing oocytes in heparin-free culture. These results are consistent with previous studies showing generally a benign effect of heparin on standard oocyte meiotic maturation. Heparin has no effect on spontaneous, FSH- or epidermal growth factor (EGF)-stimulated murine meiotic maturation (Eppig, 1981; Downs, 1989). In bovine COCs, the addition of heparin under standard IVM conditions may affect the kinetics of GVBD and possibly MI, without notably affecting COC cAMP levels (Fenton et al., 1993; Flores-Alonso et al., 2008). These minor effects of heparin in standard IVM are consistent with the almost universal use of heparin as an additive to clinical IVM collection media (human and veterinary).

It has, however, been known for decades that heparin and other glycosaminoglycans affect matrix formation and cumulus expansion of in vitro maturing COCs, albeit in a highly species-specific manner. In mice, heparin blocks hyaluronic acid synthesis and cumulus expansion of COCs stimulated by FSH, EGF, prostaglandin E or dbcAMP (Eppig, 1981), whereas heparin stimulates cumulus expansion in bovine COCs independent of FSH or cAMP (Fenton et al., 1993). Watson et al. (2012) recently found that heparin is likely to prevent mouse cumulus expansion by binding to endogenous GDF9 and disrupting its interaction with heparan sulphate proteoglycan coreceptor(s) on cumulus cells, important for GDF9 signalling and cumulus cell function in the perivitelline follicle. Hence, the addition of heparin to IVM COCs is likely to have significant effects on oocyte-secreted GDF9 signalling to cumulus cells and thereby on cumulus cell differentiation and function, although this may not account for the more acute temporal effects of heparin observed in this study on oocyte meiotic resumption and maturation.

In general, in the current study, there was a notable adverse interaction between heparin and the combined cAMP modulators on most aspects of human and mouse oocyte function assessed. Heparin further inhibited GVBD in mouse oocytes incubated with either IBMX or forskolin, and this was exacerbated when IBMX and forskolin were combined in pre-IVM. Under these pre-IVM conditions, heparin dose-dependently inhibited mouse oocyte GVBD during the IVM phase. In addition, human oocyte maturation was all but prevented when COCs were collected in heparin together with forskolin and IBMX. The mechanism by which heparin additively inhibits GVBD of GV-stage oocytes in the presence of IBMX and forskolin in pre-IVM is currently unclear.

There is no clear evidence to our knowledge that heparin affects COC cAMP levels, but heparin interrupts the actions of Ca^{2+} in COCs. In the majority of fully grown, immature mouse oocytes, repetitive transient Ca^{2+} oscillations occur every 2–3 min and last for 2–4 h soon after release from the antral follicles (Carroll et al., 1994). Ca^{2+} influx occurs in oocytes, mostly via L-type Ca^{2+} channels and gap junctions, and Ca^{2+} influx decreases as maturation progresses (Tosti et al., 2000). The acquisition of meiotic competence is related to the functionality of the inositol 1,4,5-triphosphate (IP3) pathway and, correspondingly, to the oocyte’s ability to generate spontaneous cytoplasmic IP3-dependent calcium oscillations (Lefèvre et al., 1997). Heparin is a well-known IP3 receptor antagonist and microinjection of heparin into bovine oocytes suppresses spontaneous Ca^{2+} oscillations and inhibits GVBD (Homa, 1991).

In the current study, it was evident that when mouse COCs were stimulated with forskolin, heparin interrupted the metabolism of the oocyte with decreased mitochondrial activity and ATP production. This may be as a result of interrupting the actions of high cAMP in regulating Ca^{2+} transport processes from endoplasmic reticulum (ER) to mitochondria. Increased cAMP can induce Ca^{2+} rises and the accumulation of Ca^{2+} (Dolphin, 1999), which can affect communication between the ER and mitochondria (Vandecasteele et al., 2001; Mendes et al., 2005; Szabadkai and Duchen, 2008). The ER and mitochondria are closed endomembrane networks which control different aspects of cellular metabolism. Close apposition of IP3-gated channels (IP3 receptors) to the mitochondrial surface enables the uptake of Ca^{2+} by mitochondria during cell stimulation (Vandecasteele et al., 2001; Mendes et al., 2005). Heparin prevents IP3 interacting with its receptor, and thus inhibits the Ca^{2+} release from internal stores and induces a Ca^{2+} drop. Thus, we suggest that the notably decreased oocyte metabolism may be caused by heparin-mediated interruption of cAMP/calcium intra-cellular signalling and that this, in turn, adversely affected oocyte meiotic and developmental competence.

In this study, treatment of mouse COCs during pre-IVM with IBMX and forskolin had notable positive effects on oocyte meiotic maturation, embryo cleavage and blastocyst rates and embryo quality, as well as impacting COC metabolism, particularly, mitochondrial activity and ATP availability. This is generally consistent with our previous mouse and bovine study (Albuz et al., 2010), which showed that oocyte developmental competence is improved by treating COCs at collection with either forskolin or IBMX to prevent loss of COC cAMP and to substantially increase COC cAMP levels, as occurs during in vivo oocyte maturation (Schultz et al., 1983). Perhaps, surprisingly, combined IBMX and forskolin treatment of mouse COCs during pre-IVM did not deplete the oocyte of ATP but rather significantly increased ATP production in the oocyte after 1 h. In such an in vitro scenario, when COCs are treated with forskolin, cAMP is principally generated by cumulus cells from cumulus cell ATP and is then transported to the oocyte via gap junctions (Thomas et al., 2002). The increased oocyte ATP levels after forskolin and IBMX treatment correlated to increased oocyte mitochondrial activity. cAMP can diffuse in the cell where it can set up localised gradients in subcellular structures (Zaccolo and Pozzan, 2002), and it can also be produced directly in the mitochondrial matrix by the soluble adenyllyl-cyclase localised in this compartment (Zippin et al., 2003). Cyclic nucleotide (cAMP and cGMP) PDEs have been found in the inner and outer mitochondrial membranes (Cercek and Houslay, 1982). These adenyllyl-cyclases and PDEs can modulate the mitochondrial level of cAMP (Bailie et al., 2005). In humans (Papa et al., 2001) and other mammals (Technikova-Dobrova et al., 2001), cAMP-dependent phosphorylation of complex I subunits is associated with stimulation of the NADH-ubiquinone oxidoreductase activity of the complex, resulting in enhancement of overall cellular respiration (Papa, 2006). This may be a means by which forskolin and IBMX could stimulate mitochondrial membrane potential and thereby ATP production by the
option to achieve high-blastocyst formation rates was to collect COCs during and developmental competence rates were achieved, as the use of heparin with forskolin was harmful to oocyte maturation and subsequent competence (current study), we sought to explore this interaction further in order to find an optimal medium combination for clinical COC aspiration and collection, which enhances embryo yield from IVM oocytes. When mouse COCs were collected with heparin and IBMX, but without forskolin, no adverse effect of heparin on mitochondrial membrane polarity or ATP synthesis was detected, and similar oocyte maturation and developmental competence rates were achieved, compared with the control with heparin. Moreover, a feasible option to achieve high-blastocyst formation rates was to collect COCs in medium with IBMX and heparin, then transfer to pre-IVM medium with forskolin and IBMX (IH-15 min + IF-45 min; Fig. 5). This study has confirmed that, under standard pre-IVM and IVM conditions, heparin exposure during pre-IVM has benign effects on oocyte maturation and developmental potential, but that under elevated cAMP conditions during pre-IVM, heparin adversely affects oocyte energy metabolism, oocyte meiotic maturation and subsequent embryo development. Collecting oocytes with IBMX and heparin may be a good option for pre-IVM where forskolin is used in clinical applications.

Authors’ roles
R.B.G., J.S. and H.T.Z. secured funding for the project. R.B.G., J.G.T. and H.T.Z designed the study and interpreted the results. L.G., M.D.V. and J.S. performed the human experiments, and H.T.Z. performed the majority of mouse experiments with some contributions from Z.R., X.W., M.L.S. and L.J.R. H.T.Z. and R.B.G. wrote the manuscript and all authors contributed to editing. All authors approved the final version.

Funding
This work was supported by Cook Medical with the Cook Medical Adelaide Fellowship awarded to HTZ and Cook Medical collaborative research grants awarded to the University of Adelaide and UZ Brussel. This work was also supported by an Australian National Health and Medical Research Council (NHMRC) Project Grant awarded to RBG and JS (APP1007551), NHMRC Senior Research Fellowships (APP1023210, APP627007), the National Natural Science Foundation of China (30901605, 81000248), the Fundamental Research Funds for the Central Universities (10ykpy02), and by the Belgian Institute for the Promotion of Innovation in Science and Industry (IWT-070719).

Conflict of interest
R.B.G. and J.G.T. are consultants to Cook Medical, the other authors have no conflicting interests to declare.

References
Funahashi H, Cantley TC, Day BN. Synchronization of meiosis in porcine oocytes by exposure to dibutyryl cyclic adenosine monophosphate improves developmental competence following in vitro fertilization. Biol Reprod 1997;57:49–53.
Luciano AM, Pocar P, Milanesi E, Modina S, Rieger D, Lauria A, Gandolfi F. Effect of different levels of intracellular cAMP on the in vitro maturation


